

ds

```
Set      Items  Description
S1        46   (PSGL?) (10N) (APOPTOSIS OR CELL(W) DEATH OR APOPTOTIC)
S2        17   RD S1  (unique items)
? s (psgl?) and (antibod? or immunoglobulin?) (20n) (apoptosis or cell(w)death or
apoptotic)
Processing
Processed 10 of 25 files ...
Processing
Processed 20 of 25 files ...
Completed processing all files
      3360  PSGL?
      3667988  ANTIBOD?
      1141732  IMMUNOGLOBULIN?
      903298  APOPTOSIS
      15755416  CELL
      1661678  DEATH
      439742  CELL(W) DEATH
      302978  APOPTOTIC
      48418  (ANTIBOD? OR IMMUNOGLOBULIN?) (20N) ((APOPTOSIS OR
CELL(W) DEATH) OR APOPTOTIC)
S3        30   (PSGL?) AND (ANTIBOD? OR IMMUNOGLOBULIN?) (20N) (APOPTOSIS
OR CELL(W) DEATH OR APOPTOTIC)
? rd s3
      S4        16  RD S3  (unique items)
? t s4/3/all
```

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18526114 BIOSIS NO.: 200510220614
A novel apoptosis-inducing anti-PSGL-1 antibody for T
cell-mediated diseases
AUTHOR: Huang Chiu-Chen; Lu Yi-Fen; Wen Shi-Ni; Hsieh Wen-Chuan; Lin
Yu-Chin; Liu Meng-Ru; Chiang Evelyn; Chang Chung-Nan; Lin Rong-Hwa
(Reprint)
AUTHOR ADDRESS: AbGenom Co, 2F 32 Lane 358, Juikuang Rd, Taipei, Taiwan**
Taiwan
AUTHOR E-MAIL ADDRESS: rhlin@abgenomics.com
JOURNAL: European Journal of Immunology 35 (7): p2239-2249 JUL 2005 2005
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18144876 BIOSIS NO.: 200500051941
Cross-linking of P-selectin glycoprotein ligand-1 induces death of
activated T cells
AUTHOR: Chen Shu-Ching; Huang Chiu-Chen; Chien Chung-Liang; Jeng
Chung-Jiuan; Su Ho-Ting; Chiang Evelyn; Liu Meng-Ru; Wu C H Herbert;
Chang Chung-Nan; Lin Rong-Hwa (Reprint)
AUTHOR ADDRESS: Abgenomics, 2F 32, Lane 358, Juikuang Rd, Taipei, 114, Taiwan
**Taiwan
AUTHOR E-MAIL ADDRESS: rhlin@abgenomics.com
JOURNAL: Blood 104 (10): p3233-3242 November 15, 2004 2004

MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rts. reserv.

14688087 Genuine Article#: 997QU No. References: 46
Title: Molecular characterization of rat leukocyte P-selectin glycoprotein
ligand-1 and effect of its blockade: Protection from
ischemia-reperfusion injury in liver transplantation
Author(s): Tsuchihashi S; Fondevila C; Shaw GD; Lorenz M; Marquette K;
Benard S; Shen XD; Ke BB; Busuttil RW; Kupiec-Weglinski JW (REPRINT)
Corporate Source: Univ Calif Los Angeles, David GeffenSch Med, Dumont Uiv
Calif Transplant Ctr, Dept Surg, Div Liver & Pan, 77-120 CHS, Box
957054, 10833 Le Conte Ave/Los Angeles//CA/90095 (REPRINT); Univ Calif
Los Angeles, David GeffenSch Med, Dumont Uiv Calif Transplant Ctr, Dept
Surg, Div Liver & Pan, Los Angeles//CA/90095; Wyeth
Res, Cambridge//MA/02140(jkupiec@mednet.ucla.edu)
Journal: JOURNAL OF IMMUNOLOGY, 2006, V176, N1 (JAN 1), P616-624
ISSN: 0022-1767 Publication date: 20060101
Publisher: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD
20814 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

4/3/4 (Item 1 from file: 45)
DIALOG(R)File 45:EMCare
(c) 2007 Elsevier B.V. All rts. reserv:

01050302 EMCare No: 34072646
Selectin-mediated interactions regulate cytokine networks and macrophage
heme oxygenase-1 induction in cardiac allograft recipients
Coito A.J.; Shaw G.D.; Li J.; Ke B.; Ma J.; Busuttil R.W.;
Kupiec-Weglinski J.W.
Dr. A.J. Coito, Dumont-UCLA Transplant Center, CHS, Box 957054, Los
Angeles, CA 90095 United States
AUTHOR EMAIL: acoito@mednet.ucla.edu
Laboratory Investigation (LAB. INVEST.) (United States) 2002, 82/1
(61-70)
CODEN: LAINA ISSN: 0023-6837
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 32
RECORD TYPE: Abstract
Copyright 2006 Elsevier B.V., All rights reserved.

4/3/5 (Item 1 from file: 135)
DIALOG(R)File 135:NewsRx Weekly Reports
(c) 2007 NewsRx. All rts. reserv.

0000192176 (USE FORMAT 7 OR 9 FOR FULLTEXT)
P-selectin glycoprotein ligand-1 cross-linking induces activated T cell
death
Blood Weekly, February 17, 2005, p.13

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT
WORD COUNT: 289

4/3/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.

0368313 DBR Accession No.: 2005-14019 PATENT
Novel antibody or its fragment comprising consensus sequence that binds to
cancer cell, useful for diagnosing or treating diseases such as cancer,
autoimmune diseases and inflammatory diseases - recombinant production
of an antibody useful for a disease diagnosis and therapy application
AUTHOR: PLAKSIN D; LEVANON A; SZANTON E; HAGAY Y; BEN-LEVY R; NISGAV Y
; KANFI Y
PATENT ASSIGNEE: PLAKSIN D; LEVANON A; SZANTON E; HAGAY Y; BEN-LEVY R;
NISGAV Y; KANFI Y 2005
PATENT NUMBER: US 20050069955 PATENT DATE: 20050331 WPI ACCESSION NO.:
2005-261644 (200527)
PRIORITY APPLIC. NO.: US 880922 APPLIC. DATE: 20040630
NATIONAL APPLIC. NO.: US 880922 APPLIC. DATE: 20040630
LANGUAGE: English

4/3/7 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2007 The Thomson Corp. All rts. reserv.

0361388 DBR Accession No.: 2005-07092 PATENT
Novel antibody e.g., S15 antibody or their fragments useful for purging
tumor cells from patient or for treating autoimmune diseases,
inflammatory diseases, cardiovascular diseases or retinopathic diseases
- production and purification of a single chain antibody useful for
disease therapy application
AUTHOR: PLAKSIN D; LEVANON A; SZANTON E; HAGAY Y; BEN-LEVY R; NISGAV Y
; SZRAJBER T; KANFI Y
PATENT ASSIGNEE: SAVIENT PHARM INC 2005
PATENT NUMBER: WO 200510153 PATENT DATE: 20050203 WPI ACCESSION NO.:
2005-132536 (200514)
PRIORITY APPLIC. NO.: US 611238 APPLIC. DATE: 20030630
NATIONAL APPLIC. NO.: WO 2004US21002 APPLIC. DATE: 20040630
LANGUAGE: English

4/3/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

143476399 CA: 143(26)476399c PATENT
Anti-human PSGL-1 antibodies for modulating T cell-mediated immune
response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer
INVENTOR(AUTHOR): Lin, Rong-Hwa; Chang, Chung Nan; Chen, Pei-Jiun; Huang,
Chiu-Chen
LOCATION: Taiwan,
ASSIGNEE: Abgenomics Corporation
PATENT: PCT International ; WO 2005110475 A2 DATE: 20051124
APPLICATION: WO 2005US16357 (20050510) *US 2004PV569892 (20040510)
PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A; C07K-016/28B; C12N-015/13B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;

BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG;
PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ;
UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE
; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS;
IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA;
GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

143131837 CA: 143(8)131837x PATENT
Antibodies to P-selectin glycoprotein ligand-1
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel;
Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton,
Esther; Kanfi, Yariv; Ben-levy, Rachel; Szrajber, Tali
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20050152906 A1 DATE: 20050714
APPLICATION: US 2004881405 (20040630) *US 2003PV484235 (20030630)
PAGES: 70 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424155100; A61K-039/395A; A61K-031/7072B; A61K-031/60B;
A61K-031/522B; C07K-016/30B

4/3/10 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142353888 CA: 142(19)353888h PATENT
Antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb
and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and
inflammation
INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther;
Hagay, Yocheved; Ben-levy, Rachel; Nisgav, Yael; Kanfi, Yariv
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20050069955 A1 DATE: 20050331
APPLICATION: US 2004880922 (20040630) *US 2003PV484061 (20030630)
PAGES: 74 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007100; G01N-033/53A; C07K-016/18B

4/3/11 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142349113 CA: 142(19)349113j (CORRECTION OF 142(9)148820p) PATENT
Anti-PSGL-1 antibodies, and diagnostic and therapeutic use
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel;
Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton,
Esther; Kanfi, Yariv; Ben-Levy, Rachel
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200505455 A2 DATE: 20050120
APPLICATION: WO 2004US21099 (20040630) *US 2003610840 (20030630)
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

CLASS: C07K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/12 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

142196523 CA: 142(11)196523r PATENT

Antibodies bind to sulfated epitopes involving cell rolling, metastasis, inflammation, viral entry and autoimmune disease for diagnosis, prognosis and therapy

INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther; Hagay, Yocheved; Ben-Levy, Rachel; Nisgav, Yael; Szrajber, Tali; Kanfi, Yariv

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200510153 A2 DATE: 20050203

APPLICATION: WO 2004US21002 (20040630) *US 2003611238 (20030630)

PAGES: 134 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/13 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT

Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200403166 A2 DATE: 20040108

APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)

PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;

GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/14 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

140092584 CA: 140(7)92584d PATENT
Methods for therapeutic treatment utilizing sub-clinical amount of a
therapeutic agent combined with or conjugated to an antibody, or fragment
thereof
INVENTOR(AUTHOR): Lazarovits, Janette; Nimrod, Abraham; Hoch-Mar-Chaim,
Hagit; Levanon, Avigdor
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200402528 A1 DATE: 20040108
APPLICATION: WO 2003US20604 (20030630) *US 189025 (20020701)
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A; A61K-051/00B; A61K-038/00B; A61K-039/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/15 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

140092576 CA: 140(7)92576c PATENT
Antibodies specific to epitopes involving cell rolling, metastasis and
inflammation for diagnosis and treatment of cancer, metastasis, leukemia,
autoimmune disease and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel;
Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter,
Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101
APPLICATION: US 32423 (20011231) *US PV258948 (20001229)
PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B;
C07K-014/16B; C07K-007/08B; C07K-007/06B

4/3/16 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

138071663 CA: 138(6)71663x JOURNAL
CD62-PSGL-1 interactions regulate cytokine chemokine and apoptotic
networks in cardiac allograft recipients
AUTHOR(S): Coito, A. J.; Shaw, G. D.; Meng, L.; Moore, C.; Ma, J.;
Busuttil, R. W.; Kupiec-Weglinski, J. W.
LOCATION: Department of Surgery, Dumont-UCLA Transplant Center, UCLA
School of Medicine, Los Angeles, CA, USA
JOURNAL: Transplant. Proc. (Transplantation Proceedings) DATE: 2002
VOLUME: 34 NUMBER: 5 PAGES: 1463-1464 CODEN: TRPPA8 ISSN: 0041-1345
PUBLISHER ITEM IDENTIFIER: 0041-1345(02)02931-7 LANGUAGE: English
PUBLISHER: Elsevier Science Inc.
? t s4/7/16
>>>Format 7 is not valid in file 143

4/7/16 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

138071663 CA: 138(6)71663x JOURNAL
CD62-PSGL-1 interactions regulate cytokine chemokine and apoptotic
networks in cardiac allograft recipients
AUTHOR(S): Coito, A. J.; Shaw, G. D.; Meng, L.; Moore, C.; Ma, J.;
Busuttil, R. W.; Kupiec-Weglinski, J. W.
LOCATION: Department of Surgery, Dumont-UCLA Transplant Center, UCLA
School of Medicine, Los Angeles, CA, USA
JOURNAL: Transplant. Proc. (Transplantation Proceedings) DATE: 2002
VOLUME: 34 NUMBER: 5 PAGES: 1463-1464 CODEN: TRPPA8 ISSN: 0041-1345
PUBLISHER ITEM IDENTIFIER: 0041-1345(02)02931-7 LANGUAGE: English
PUBLISHER: Elsevier Science Inc.
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: CD26 P selectin glycoprotein ligand 1 cytokine chemokine,
cardiac allograft rejection apoptosis cytokine selectin
DESCRIPTORS:
Transplant and Transplantation...
allotransplant, heart; CD62-PSGL-1 interactions regulate cytokine
chemokine and apoptotic networks in cardiac allograft recipients
Heart... Transplant rejection...
allotransplant; CD62-PSGL-1 interactions regulate cytokine chemokine
and apoptotic networks in cardiac allograft recipients
Selectins... Apoptosis... Interleukin 1 β ... Monocyte chemoattractant
protein-1... Interleukin 2...
CD62-PSGL-1 interactions regulate cytokine chemokine and apoptotic
networks in cardiac allograft recipients
Interferons...
 γ ; CD62-PSGL-1 interactions regulate cytokine chemokine and
apoptotic networks in cardiac allograft recipients
Glycoproteins...
PSGL-1 (P-selectin glycoprotein ligand-1), ig conjugates; PSGL-1-Ig
suppresses apoptosis and cytokine formation in cardiac allograft
recipients
Glycoproteins...
PSGL-1 (P-selectin glycoprotein ligand-1); CD62-PSGL-1 interactions
regulate cytokine chemokine and apoptotic networks in cardiac allograft
recipients
Immunoglobulins...
PSGL-1 conjugates; PSGL-1-Ig suppresses apoptosis and cytokine
formation in cardiac allograft recipients
Immunotherapy... Immunosuppressants...
PSGL-1-Ig suppresses apoptosis and cytokine formation in cardiac
allograft recipients
CAS REGISTRY NUMBERS:

9059-22-7 1; CD62-PSGL-1 interactions regulate cytokine chemokine and
apoptotic networks in cardiac allograft recipients

? t s4/kwic/14

>>>KWIC option is not available in file(s): 399

? ds

Set	Items	Description
S1	46	(PSGL?) (10N) (APOPTOSIS OR CELL(W)DEATH OR APOPTOTIC)
S2	17	RD S1 (unique items)
S3	30	(PSGL?) AND (ANTIBOD? OR IMMUNOGLOBULIN?) (20N) (APOPTOSIS OR CELL(W)DEATH OR APOPTOTIC)
S4	16	RD S3 (unique items)
?		

10

11apr07 08:47:35 User208760 Session D2846.1
\$0.48 0.137 DialUnits File1
\$0.48 Estimated cost File1
\$0.48 Estimated cost this search
\$0.48 Estimated total session cost 0.137 DialUnits

File 410:Dialog Comm.-of-Interest Newsletters 2007 /Feb
(c) 2007 Dialog

Set	Items	Description
-----	-------	-------------

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

11apr07 08:47:40 User208760 Session D2846.2
\$0.00 0.115 DialUnits File410
\$0.00 Estimated cost File410
\$0.02 TELNET
\$0.02 Estimated cost this search
\$0.50 Estimated total session cost 0.253 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2007/Apr W1

(c) 2007 The Thomson Corporation

*File 5: BIOSIS has been enhanced with archival data. Please see
HELP NEWS 5 for information.

File 73:EMBASE 1974-2007/Apr 09

(c) 2007 Elsevier B.V.

File 155:MEDLINE(R) 1950-2007/Apr 09

(c) format only 2007 Dialog

File 399:CA SEARCH(R) 1967-2007/UD=14616

(c) 2007 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set	Items	Description
-----	-------	-------------

? s (psgl?)(20n)(antibod? or immunoglobulin?)(20n)(kpl1 or y1 or y17 or l32)

1946 PSGL?

2214816 ANTIBOD?

819962 IMMUNOGLOBULIN?

33 KPL1

9131 Y1

37 Y17

845 L32

S1 18 (PSGL?)(20N)(ANTIBOD? OR IMMUNOGLOBULIN?)(20N)(KPL1 OR Y1
OR Y17 OR L32)

? rd s1

S2 7 RD S1 (unique items)

? t s2/3/all

2/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

19306113 BIOSIS NO.: 200600651508

A high affinity human antibody antagonist of P-selectin mediated rolling

AUTHOR: Swers Jeffrey S; Widom Angela; Phan Uyen; Springer Timothy A;

Wittrup K Dane (Reprint)

AUTHOR ADDRESS: MIT, Dept Chem Engrn, 66-552,25 Ames St, Cambridge, MA 02139

USA**USA

AUTHOR E-MAIL ADDRESS: wittrup@mit.edu

JOURNAL: Biochemical and Biophysical Research Communications 350 (3): p
508-513 NOV 24 2006 2006
ISSN: 0006-291X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18258361 BIOSIS NO.: 200500164533
Signaling function of PSGL-1 in neutrophil:
tyrosine-phosphorylation-dependent and c-Abl-involved alteration in the
F-actin-based cytoskeleton
AUTHOR: Ba Xueqing; Chen Cuixia; Gao Yanguang; Zeng Xianlu (Reprint)
AUTHOR ADDRESS: Inst Cytol and Genet, NE Normal Univ, Changchun, 130024,
China**China
AUTHOR E-MAIL ADDRESS: zengx779@nenu.edu.cn
JOURNAL: Journal of Cellular Biochemistry 94 (2): p365-373 February 1,
2005 2005
MEDIUM: print
ISSN: 0730-2312 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16943708 BIOSIS NO.: 200200537219
Binding of function-blocking mAbs to mouse and human P-selectin
glycoprotein ligand-1 peptides with and without tyrosine sulfation
AUTHOR: Thatte Aravinda; Ficarro Scott; Snapp Karen R; Wild Martin K;
Vestweber Dietmar; Hunt Donald F; Ley Klaus F (Reprint)
AUTHOR ADDRESS: Department of Biomedical Engineering, Cardiovascular
Research Center, University of Virginia, MRS Building, Room 1013, Box
801394, Charlottesville, VA, 22908-1394, USA**USA
JOURNAL: Journal of Leukocyte Biology 72 (3): p470-477 September, 2002
2002
MEDIUM: print
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

14322290 BIOSIS NO.: 199800116537
Functional characterization of L-selectin ligands on human neutrophils and
leukemia cell lines: Evidence for mucinlike ligand activity distinct from
P-selectin glycoprotein ligand-1
AUTHOR: Ramos Carroll L; Smith McRae J; Snapp Karen R; Kansas Geoffrey S;
Stickney George W; Ley Klaus; Lawrence Michael B
AUTHOR ADDRESS: Dep. Biomedical Engineering, Univ. Virginia, Box 377,
Health Sci. Cent., Charlottesville, VA 22908, USA**USA
JOURNAL: Blood 91 (3): p1067-1075 Feb. 1, 1998 1998
MEDIUM: print

ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

14277514 BIOSIS NO.: 199800071761
A novel P-selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L-selectin
AUTHOR: Snapp Karen R; Ding Han; Atkins Kristin; Warnke Roger; Luscinskas Francis W; Kansas Geoffrey S (Reprint)
AUTHOR ADDRESS: Dep. Microbiol.-Immunol., Northwestern Med. Sch., 303 E. Chicago Ave., Chicago, IL 60611, USA**USA
JOURNAL: Blood 91 (1): p154-164 Jan. 1, 1998 1998
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

143131837 CA: 143(8)131837x PATENT
Antibodies to P-selectin glycoprotein ligand-1
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel; Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton, Esther; Kanfi, Yariv; Ben-levy, Rachel; Szrajber, Tali
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20050152906 A1 DATE: 20050714
APPLICATION: US 2004881405 (20040630) *US 2003PV484235 (20030630)
PAGES: 70 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424155100; A61K-039/395A; A61K-031/7072B; A61K-031/60B; A61K-031/522B; C07K-016/30B

2/3/7 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142349113 CA: 142(19)349113j (CORRECTION OF 142(9)148820p) PATENT
Anti-PSGL-1 antibodies, and diagnostic and therapeutic use
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel; Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton, Esther; Kanfi, Yariv; Ben-Levy, Rachel
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200505455 A2 DATE: 20050120
APPLICATION: WO 2004US21099 (20040630) *US 2003610840 (20030630)
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;

PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG
? t s2/7/1-5

2/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19306113 BIOSIS NO.: 200600651508
A high affinity human antibody antagonist of P-selectin mediated rolling
AUTHOR: Swers Jeffrey S; Widom Angela; Phan Uyen; Springer Timothy A;
Wittrup K Dane (Reprint)
AUTHOR ADDRESS: MIT, Dept Chem Engrn, 66-552,25 Ames St, Cambridge, MA 02139
USA**USA
AUTHOR E-MAIL ADDRESS: wittrup@mit.edu
JOURNAL: Biochemical and Biophysical Research Communications 350 (3): p
508-513 NOV 24 2006 2006
ISSN: 0006-291X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: We have characterized the IgG form of a previously isolated and
engineered single-chain Fv (scFv), named RR2r3s4-1, that binds to human
PSGL -1. This fully human IgG was determined to have a K-d of 1.8
+/- 0.7 nM by fluorescence quenching titration. It better inhibits
P-selectin-PSGL-1 interactions than a commercially available murine
monoclonal antibody KPL1 and better inhibits neutrophil
rolling than ***KPL1***. Thus, RR2r3s4-1 is the most effective
antibody at inhibiting P-selectin- ***PSGL*** -1 interactions known.
Specificity analysis reveals that RR2r3s4-1 does not cross react with
murine PSGL-1 and thus requires more than tyrosine sulfate for
binding to human ***PSGL*** -1. This evidence demonstrates the therapeutic
potential of this antibody as a potent anti-inflammatory
therapeutic. (c) 2006 Elsevier Inc. All rights reserved.

2/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18258361 BIOSIS NO.: 200500164533
Signaling function of PSGL-1 in neutrophil:
tyrosine-phosphorylation-dependent and c-Abl-involved alteration in the
F-actin-based cytoskeleton
AUTHOR: Ba Xueqing; Chen Cuixia; Gao Yanguang; Zeng Xianlu (Reprint)
AUTHOR ADDRESS: Inst Cytol and Genet, NE Normal Univ, Changchun, 130024,
China**China
AUTHOR E-MAIL ADDRESS: zengx779@nenu.edu.cn
JOURNAL: Journal of Cellular Biochemistry 94 (2): p365-373 February 1,
2005 2005
MEDIUM: print
ISSN: 0730-2312 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: P-selectin glycoprotein ligand-1 (PSGL-1) is the
best-characterized selectin ligand that has been demonstrated to mediate
leukocytes rolling on endothelium and leukocytes recruitment into

inflamed tissue in vivo. In addition to its direct role in leukocyte capturing, ***PSGL*** -1 also functions as a signal-transducing receptor. The present work showed that after cross-linking of PSGL-1 with KPL1, an anti-PSGL-1 monoclonal antibody, PSGL-1 linked to the cytoskeleton and became a detergent-insoluble component in activated neutrophils. The ***antibody*** cross-linking led to the polymerization and redistribution of F-actin-based cytoskeleton, and this alteration of cytoskeleton was spatiotemporally related to the polarization of PSGL-1. PSGL-1's polarization was cytoskeleton-dependent because it was eliminated by cytochalasin B. Furthermore, the polymerization and redistribution of F-actin filaments were tyrosine-phosphorylation-dependent since the alteration of F-actin-based cytoskeleton was severely blocked by genistein, a universal tyrosine kinase inhibitor. ST1571, a small molecule inhibitor for cytoplasmic tyrosine kinase c-Abl, also inhibited the alteration of F-actin-based cytoskeleton, and c-Abl was redistributed to where F-actin concentrated in the activated neutrophils. The results suggested that cross-linking of PSGL-1 induces the phosphorylation-dependent and c-Abl-involved alteration of F-actin-based cytoskeleton in neutrophils. Copyright 2004 Wiley-Liss, Inc.

2/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16943708 BIOSIS NO.: 200200537219
Binding of function-blocking mAbs to mouse and human P-selectin glycoprotein ligand-1 peptides with and without tyrosine sulfation
AUTHOR: Thatte Aravinda; Ficarro Scott; Snapp Karen R; Wild Martin K; Vestweber Dietmar; Hunt Donald F; Ley Klaus F (Reprint)
AUTHOR ADDRESS: Department of Biomedical Engineering, Cardiovascular Research Center, University of Virginia, MRS Building, Room 1013, Box 801394, Charlottesville, VA, 22908-1394, USA**USA
JOURNAL: Journal of Leukocyte Biology 72 (3): p470-477 September, 2002
2002
MEDIUM: print
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: P-selectin glycoprotein ligand-1 (PSGL-1) mediates rolling of leukocytes on P-selectin-expressing endothelial cells under shear flow. Function-blocking monoclonal antibodies (mAbs) against mouse and human PSGL-1 recognize an anionic segment at the N-terminus of PSGL-1. High affinity interaction of ***PSGL*** -1 with P-selectin requires sulfation of tyrosines 46, 48, and 51 (human) or 54 and 56 (mouse). We tested binding of two anti-human (KPL1 and PL1) and two anti-mouse (4RA10 and 2PH1) PSGL-1 mAbs to synthetic peptides of N-terminus of human and mouse PSGL-1 and found binding to be independent of tyrosine sulfation. In peptide-blocking experiments, sulfated and nonsulfated human and mouse peptides competed with antibody binding to PSGL-1 expressed on myeloid cells. Arylsulfatase treatment significantly reduced P-selectin binding but had no effect on antibody binding. Our data show, in three independent assay systems, that function-blocking antibodies to mouse or human PSGL-1 do not require sulfation of N-terminal tyrosines for binding.

2/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

14322290 BIOSIS NO.: 199800116537

Functional characterization of L-selectin ligands on human neutrophils and leukemia cell lines: Evidence for mucinlike ligand activity distinct from P-selectin glycoprotein ligand-1

AUTHOR: Ramos Carroll L; Smith McRae J; Snapp Karen R; Kansas Geoffrey S; Stickney George W; Ley Klaus; Lawrence Michael B

AUTHOR ADDRESS: Dep. Biomedical Engineering, Univ. Virginia, Box 377, Health Sci. Cent., Charlottesville, VA 22908, USA**USA

JOURNAL: Blood 91 (3): p1067-1075 Feb. 1, 1998 1998

MEDIUM: print

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Recent reports have shown that leukocyte-leukocyte adhesion is dependent on L-selectin and that leukocyte recognition of L-selectin may be mediated by P-selectin glycoprotein ligand-1 (PSGL-1). We show that the specific attachment and rolling of human neutrophils and the leukemia cell lines HL-60 and U937 on immobilized, purified L-selectin under continuous shear stress is only partially inhibited by treatment with the PSGL-1 monoclonal antibody (MoAb), KPL1 (41% to 53% inhibition), suggesting that L-selectin ligand activity in addition to ***PSGL*** -1 may mediate myeloid cell rolling on L-selectin. K562 cells cotransfected with cDNAs encoding alpha(1,3)fucosyltransferase-VII (FucT-VII) and ***PSGL*** -1 rolled on L-selectin. Adhesion of FucT-VII-PSGL-1 transfectants to L-selectin was completely blocked by MoAb KPL1, indicating that both L-selectin and P-selectin bind similar sites on ***PSGL*** -1. In support of existence of a non- ***PSGL*** -1 L-selectin ligand activity on leukocytes, an HL-60 membrane preparation immunodepleted of PSGL-1 supported rolling of L-selectin, but not P-selectin transfectants. Treatment of HL-60 cells with O-sialoglycoprotein endopeptidase inhibited attachment and rolling on L-selectin and P-selectin. However, neuraminidase treatment completely blocked HL-60 rolling on L-selectin, but not P-selectin, suggesting L-selectin and P-selectin ligand activities have different contributions of sialic acid. These findings indicate that myeloid cells express sialylated, O-linked glycoprotein ligand activity independent of PSGL-1 that supports L-selectin-mediated rolling.

2/7/5 (Item 5 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

14277514 BIOSIS NO.: 199800071761

A novel P-selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L-selectin

AUTHOR: Snapp Karen R; Ding Han; Atkins Kristin; Warnke Roger; Luscinskas Francis W; Kansas Geoffrey S (Reprint)

AUTHOR ADDRESS: Dep. Microbiol.-Immunol., Northwestern Med. Sch., 303 E. Chicago Ave., Chicago, IL 60611, USA**USA

JOURNAL: Blood 91 (1): p154-164 Jan. 1, 1998 1998

MEDIUM: print

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Interactions between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) mediate the earliest "rolling" of leukocytes on the luminal surface of endothelial cells at sites of inflammation. Previously, PSGL-1 has been shown to be the primary mediator of

interactions between neutrophils and P-selectin, but studies on the ability of PSGL-1 to mediate interactions between P-selectin and other subsets of leukocytes have yielded variable and conflicting results. A novel IgG monoclonal antibody (MoAb) to human PSGL-1 was generated, and the specificity of this MoAb was confirmed by both flow cytometric analysis and Western blotting of cells transfected with human

PSGL -1. This newly developed MoAb, ***KPL1***, inhibited interactions between P-selectin expressing COS cells and either HL60 cells, neutrophils, or lymphocytes. Furthermore, ***KPL1*** completely inhibited interactions between P-selectin and either purified CD4 T cells or neutrophils in a flow assay under physiological conditions, but had no effect on interactions of T cells or neutrophils with E-selectin. In addition, KPL1 blocked interactions between lymphoid cells transfected with L-selectin and COS cells expressing PSGL-1. The KPL1 epitope was mapped to a site within a consensus tyrosine sulfation motif of PSGL-1, previously shown to be essential for interaction with P-selectin and now shown to be essential for interaction with L-selectin, and to be distinct from the epitope identified by the PL1 function blocking anti-PSGL-1 MoAb. Two-color flow cytometry of normal leukocytes showed that while natural killer (NK) cells (CD16+), monocytes, CD4 and CD8 T cells, and alpha/beta and gamma/delta T cells were uniformly positive for PSGL-1, B cells expressed low levels of the KPL1 epitope. This low level of KPL1 staining was also observed immunohistologically in germinal centers, which had no detectable KPL1 staining, whereas T-cell areas (interfollicular region) were positive for KPL1. Interestingly, plasma cells in situ and interleukin-6-dependent myeloma cell lines were KPL1+. Thus, PSGL-1 is expressed on essentially all blood neutrophils, NK cells, B cells, T cells, and monocytes. Variation in tyrosine sulfation during B-cell differentiation may affect the ability of B cells to interact with P- and L-selectin.

?

st is in DialUnits

? b 410

11apr07 08:04:18 User208760 Session D2845.1
\$0.62 0.178 DialUnits File1
\$0.62 Estimated cost File1
\$0.62 Estimated cost this search
\$0.62 Estimated total session cost 0.178 DialUnits

File 410:Dialog Comm.-of-Interest Newsletters 2007 /Feb
(c) 2007 Dialog

Set	Items	Description
-----	-------	-------------

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin biotech

11apr07 08:04:23 User208760 Session D2845.2
\$0.00 0.117 DialUnits File410
\$0.00 Estimated cost File410
\$0.02 TELNET
\$0.02 Estimated cost this search
\$0.64 Estimated total session cost 0.295 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2007/Apr W1

(c) 2007 The Thomson Corporation

*File 5: BIOSIS has been enhanced with archival data. Please see
HELP NEWS 5 for information.

File 6:NTIS 1964-2007/Apr W2

(c) 2007 NTIS, Intl Cpyrght All Rights Res

File 8:Ei Compendex(R) 1884-2007/Apr W1

(c) 2007 Elsevier Eng. Info. Inc.

File 24:CSA Life Sciences Abstracts 1966-2007/Dec

(c) 2007 CSA.

File 34:SciSearch(R) Cited Ref Sci 1990-2007/Apr W1

(c) 2007 The Thomson Corp

File 45:EMCare 2007/Apr W1

(c) 2007 Elsevier B.V.

File 65:Inside Conferences 1993-2007/Apr 10

(c) 2007 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2007/Apr W2

(c) 2007 Elsevier B.V.

File 73:EMBASE 1974-2007/Apr 09

(c) 2007 Elsevier B.V.

File 98:General Sci Abs 1984-2007/Apr

(c) 2007 The HW Wilson Co.

File 99:Wilson Appl. Sci & Tech Abs 1983-2007/Mar

(c) 2007 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2007/Apr W1

(c) 2007 NewsRx

File 136:BioEngineering Abstracts 1966-2007/Dec

(c) 2007 CSA.

File 143:Biol. & Agric. Index 1983-2007/Mar

(c) 2007 The HW Wilson Co

File 144:Pascal 1973-2007/Apr W1

(c) 2007 INIST/CNRS

File 155:MEDLINE(R) 1950-2007/Apr 09

(c) format only 2007 Dialog

File 172:EMBASE Alert 2007/Apr 09

(c) 2007 Elsevier B.V.

File 266:FEDRIP 2007/Mar

Comp & dist by NTIS, Intl Copyright All Rights Res

File 315:ChemEng & Biotec Abs 1970-2007/Feb

(c) 2007 DECHEMA

File 357:Derwent Biotech Res. _1982-2007/Apr W2

(c) 2007 The Thomson Corp.

File 358:Current BioTech Abs 1983-2006/Jan

(c) 2006 DECHEMA

*File 358: This file is no longer updating. Please use File 315, which includes all File 358 records and updates.

File 369:New Scientist 1994-2007/Dec W1

(c) 2007 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2007/UD=14616

(c) 2007 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 2006 The Thomson Corp

Set Items Description

? s (psgl?) (10n) (apoptosis or cell(w)death or apoptotic)

Processing

Processed 10 of 25 files ...

Processing

Completed processing all files

3360 PSGL?

903298 APOPTOSIS

15755416 CELL

1661678 DEATH

439742 CELL(W)DEATH

302978 APOPTOTIC

S1 46 (PSGL?) (10N) (APOPTOSIS OR CELL(W)DEATH OR APOPTOTIC)

? rd s1

S2 17 RD S1 (unique items)

? t s2/7/all

>>>Format 7 is not valid in file 143

2/7/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18526114 BIOSIS NO.: 200510220614

A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases

AUTHOR: Huang Chiu-Chen; Lu Yi-Fen; Wen Shi-Ni; Hsieh Wen-Chuan; Lin Yu-Chin; Liu Meng-Ru; Chiang Evelyn; Chang Chung-Nan; Lin Rong-Hwa (Reprint)

AUTHOR ADDRESS: AbGenom Co, 2F 32 Lane 358, Juikuang Rd, Taipei, Taiwan** Taiwan

AUTHOR E-MAIL ADDRESS: rhlin@abgenomics.com

JOURNAL: European Journal of Immunology 35 (7): p2239-2249 JUL 2005 2005

ISSN: 0014-2980

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: We previously discovered a hamster monoclonal antibody, TAB4, against mouse PSGL1/CD162 that can induce death of activated T cells.

Here, we further investigated the potential of TAB4 in treating two murine models of T cell-mediated diseases. The results showed that administration of TAB4 suppressed incidence and severity of both GVHD and type I diabetes. Analyses of apoptotic T cells ex vivo shortly after antibody injection revealed a higher percentage of apoptosis among activated T cells in the TAB4-treated group than in the control group. Furthermore, restoration of functional donor T cells was observed in TAB4-treated mice. As TAB4 does not affect the binding of P-selectin to activated T cells, our data suggest that its long-lasting therapeutic effect on inhibiting disease progression is attained by specifically inducing apoptosis of activated T cells. These data hence extend our previous finding of the novel property of PSGL-1 and strongly indicate that the PSGL-1-specific apoptosis-inducing antibody is a new therapeutic agent possessing a great potential for controlling GVHD and other T cell-mediated autoimmune diseases.

2/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18144876 BIOSIS NO.: 200500051941
Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells
AUTHOR: Chen Shu-Ching; Huang Chiu-Chen; Chien Chung-Liang; Jeng Chung-Jiuan; Su Ho-Ting; Chiang Evelyn; Liu Meng-Ru; Wu C H Herbert; Chang Chung-Nan; Lin Rong-Hwa (Reprint)
AUTHOR ADDRESS: Abgenomics, 2F 32, Lane 358, Juikuang Rd, Taipei, 114, Taiwan
**Taiwan
AUTHOR E-MAIL ADDRESS: rhlin@abgenomics.com
JOURNAL: Blood 104 (10): p3233-3242 November 15, 2004 2004
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Increasing evidence has shown that death signaling in T cells is regulated in a complicated way. Molecules other than death receptors can also trigger T-cell death. Here, we demonstrate for the first time that P-selectin glycoprotein ligand-1 (PSGL-1) or CD162 molecules crosslinked by an anti-PSGL-1 monoclonal antibody, TAB4, can trigger a death signal in activated T cells. In contrast to classic ***cell*** ***death***, ***PSGL*** -1-mediated T- ***cell*** ***death*** is caspase independent. It involves translocation of apoptosis-inducing factor from mitochondria to nucleus and mitochondrial cytochrome c release. Ultrastructurally, both peripheral condensation of chromatin and apoptotic body were observed in PSGL-1-mediated T- ***cell*** ***death***. Collectively, this study demonstrates a novel role for PSGL-1 in controlling activated T-cell death and, thus, advances our understanding of immune regulation. Copyright 2004 by The American Society of Hematology.

2/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17791095 BIOSIS NO.: 200400158436
Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of PSGL-1.

AUTHOR: Winkler Ingrid G (Reprint); Snapp Karen R; Simmons Paul J; Levesque Jean-Pierre
AUTHOR ADDRESS: Adhesive Interactions and Cell Trafficking Laboratory,
Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, Melbourne,
VIC, 8006, Australia**Australia
AUTHOR E-MAIL ADDRESS: ingrid.winkler@petermac.org
JOURNAL: Blood 103 (5): p1685-1692 March 1, 2004 2004
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Although both P- and E-selectin are constitutively expressed on bone marrow endothelial cells, their role in the regulation of hematopoiesis has only recently been investigated. We have previously shown that P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is expressed by primitive human bone marrow CD34+ cells, mediates their adhesion to P-selectin, and, more importantly, inhibits their proliferation. We now demonstrate that adhesion to E-selectin inhibits the proliferation of human CD34+ cells isolated either from human umbilical cord blood, adult mobilized blood, or steady-state bone marrow. Furthermore, a subpopulation, which does not contain the most primitive hematopoietic progenitor cells, undergoes apoptosis following E-selectin-mediated adhesion. The same phenomenon was observed in cells isolated from mouse bone marrow. Using lineage-negative Sca-1+ c-KIT+ bone marrow cells from PSGL-1-/- and wild-type mice, we establish that PSGL-1 is not the ligand involved in E-selectin-mediated growth inhibition and apoptosis. Moreover, stable transfection of the human myeloid cell line K562 (which does not express PSGL-1) with alpha(1,3) fucosyltransferase VII alone was sufficient to recapitulate the E-selectin-mediated growth inhibition and apoptosis observed in hematopoietic progenitor cells. These data demonstrate that an E-selectin ligand(s) other than PSGL-1 transduces growth inhibitory and proapoptotic signals and requires posttranslational fucosylation to be functional.

2/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17707854 BIOSIS NO.: 200400074110
CD62-PSGL-1 interactions regulate cytokine chemokine and
apoptotic networks in cardiac allograft recipients.
AUTHOR: Coito A J (Reprint); Shaw G D; Meng L; Moore C; Ma J; Busuttil R W;
Kupiec-Weglinski J W
AUTHOR ADDRESS: Dumont-UCLA Transplant Center, Room 77-120 CHS, Box 957054,
Los Angeles, CA, 90095, USA**USA
AUTHOR E-MAIL ADDRESS: acoito@mednet.ucla.edu
JOURNAL: Transplantation Proceedings. 34 (5): p1463-1464 August 2002 2002
MEDIUM: print
ISSN: 0041-1345
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: English

2/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16667939 BIOSIS NO.: 200200261450

Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells
AUTHOR: Winkler Ingrid G (Reprint); Eto Tetsuya (Reprint); Purton Louise E (Reprint); Haylock David N (Reprint); Snapp Karen R; Kansas Geoffrey S; Simmons Paul J (Reprint); Levesque Jean-Pierre (Reprint)
AUTHOR ADDRESS: Stem Cell Biology Laboratory, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia**Australia
JOURNAL: Blood 98 (11 Part 1): p797a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Adhesive interactions are critical to the regulation and localization of hematopoiesis to the bone marrow (BM). In previous work, we demonstrated that the P-selectin receptor PSGL-1/CD162 is expressed by human BM CD34+ cells mediating adhesion to P-selectin and resulting in growth inhibition (Levesque JP, et al Immunity 1999; 11:369-378). We now demonstrate that CD34+ cells isolated from either cord blood, mobilized blood or steady-state BM adhere to recombinant E-selectin in a dose-dependent manner. Unlike adhesion to P-selectin, adhesion to E-selectin is not inhibited by pre-treatment of cells by either Pasteurella haemolytica O-sialoglycoprotein endopeptidase, or the function-blocking anti-PSGL-1 monoclonal antibodies KPL-1 and PL1. Moreover, we show that the growth of human CD34+ and CD34+CD38- cells is inhibited following adhesion to E-selectin and that this inhibition involves in part apoptosis of a cell population that does not contain the most primitive HPC. We further demonstrate that this phenomenon is not restricted to human HPC but also occurs in the mouse. Lin- Sca1+ c-KIT+ as well as Lin- Rhodull cell populations isolated from C57Bl6J mouse BM express PSGL-1 and adhere to both P- and E-selectin. Furthermore, adhesion to either P- or E-selectin inhibits their growth in culture. These findings are consistent with reports showing that targeted gene deletion of both P- and E-selectin genes is required to observe abnormal trafficking, homing, engraftment and cycling status of hematopoietic progenitor and stem cells. To assess whether ***PSGL*** -1 is responsible for E-selectin-mediated growth inhibition and apoptosis in hematopoietic cells, we used the human myeloid leukemia cell line K562. K562 cells cannot adhere to either P- or E-selectin due to the absence of expression of both PSGL-1 and the alpha(1,3)fucosyltransferase FucT-VII necessary for post-translational glycosylation of functional selectin receptors. We show that stable transduction of FucT-VII alone renders K562 adherent to E-selectin but not to P-selectin and more importantly, susceptible to E-selectin-mediated growth inhibition and apoptosis. These findings show that E-selectin mediates growth inhibition of hematopoietic cells through unique fucosylated receptors which are distinct from PSGL-1.

2/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15251034 BIOSIS NO.: 199900510694
PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in suppression of hematopoiesis
AUTHOR: Levesque Jean-Pierre; Zannettino Andrew C W; Pudney Melanie; Niutta Silvana; Haylock David N; Snapp Karen R; Kansas Geoffrey S; Berndt

Michael C; Simmons Paul J (Reprint)
AUTHOR ADDRESS: Hanson Centre for Cancer Research, Matthew Roberts
Laboratory, Division of Haematology, Institute of Medical and Veterinary
Science, Adelaide, SA, 5000, Australia**Australia
JOURNAL: Immunity 11 (3): p369-378 Sept., 1999 1999
MEDIUM: print
ISSN: 1074-7613
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Cellular interactions are critical for the regulation of hematopoiesis. The sialomucin PSGL-1/CD162 mediates the attachment of mature leukocytes to P-selectin. We now show that PSGL-1 also functions as the sole receptor for P-selectin on primitive human CD34+ hematopoietic progenitor cells (HPC). More importantly, ligation of PSGL-1 by immobilized or soluble ligand or anti-PSGL-1 antibody results in a profound suppression of HPC proliferation stimulated by potent combinations of early acting hematopoietic growth factors. These data demonstrate an unanticipated but extremely marked growth-inhibitory effect of P-selectin on hematopoiesis and provide direct evidence that PSGL-1, in addition to its well-documented role as an adhesion molecule on mature leukocytes, is a potent negative regulator of human hematopoietic progenitors.

2/7/7 (Item 1 from file: 34)
DIALOG(R) File 34:SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rts. reserv.

15385547 Genuine Article#: 066CS Number of References: 22
Title: Rolling and adhesion of apoptotic monocytes is impaired by loss of functional cell surface-expressed P-selectin glycoprotein ligand-1
Author(s): Van Genderen H; Wielders SJH; Lindhout T; Reutelingsperger CPM (REPRINT)
Corporate Source: Univ Limburg, Cardiovasc Res Inst Maastricht, Dept Biochem, POB 616/NL-6200 MD Maastricht//Netherlands/ (REPRINT); Univ Limburg, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht//Netherlands/(c.reutelingsperger@bioch.unimaas.nl)
Journal: JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, V4, N7 (JUL), P 1611-1617
ISSN: 1538-7933 Publication date: 20060700
Publisher: BLACKWELL PUBLISHING, 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND

Language: English Document Type: ARTICLE

Abstract: Background: Apoptosis induces cellular membrane changes that are thought to be linked to thrombotic processes, for example, surface exposure of procoagulant phosphatidylserine (PtdSer), upregulation of tissue factor (TF), and microvesicle formation. The latter, though, could downregulate this cellular response by shedding prothrombotic membrane elements, for example, integrins and TF. To test this hypothesis, etoposide-treated, apoptotic, monocytic cells (human monocytic leukemia cell line [THP-1]) were examined for rolling and adhesion on adherent platelets and for TF expression. Methods and results: Etoposide treatment did not result in a significant change in TF antigen expression. However, TF activity, measured in a continuous factor Xa generation assay, was increased fivefold concomitantly with increased exposure of PtdSer. Laminar flow adhesion assays specific for interaction between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) revealed that in contrast to non-treated cells, apoptotic cells did not roll or firmly attach on adherent platelets. Lack of apoptotic THP-1 platelet interaction could be

attributed to both a loss of cell surface-expressed PSGL-1 and loss of functional PSGL-1 as a result of disruption of the binding of ***PSGL*** -1 with the cytoskeleton. Conclusion: Etoposide-induced apoptosis in THP-1 cells evokes a procoagulant response by increasing TF activity associated with an increased PtdSer exposure. However, in contrast to TF, PSGL-1 shedding and loss of function, makes that apoptotic monocytes are unlikely involved in a thrombotic action because of their inability to adhere to an injured vessel wall or developing thrombus.

2/7/8 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rts. reserv.

15169659 Genuine Article#: BEE03 Number of References: 16
Title: The interactions of Anaplasma phagocytophilum, endothelial cells, and human neutrophils
Author(s): Herron MJ; Ericson ME; Kurtti TJ; Munderloh UG (REPRINT)
Corporate Source: Univ Minnesota, Dept Entomol, 219 Hodson Hall, 1980 Folwell Ave/St Paul//MN/55108 (REPRINT); Univ Minnesota, Dept Entomol, St Paul//MN/55108; Univ Minnesota, Dept Dermatol, Minneapolis//MN/55455 (munde001@umn.edu)
, 2005, V1063, P374-382
ISSN: 0077-8923 Publication date: 20050000
Publisher: NEW YORK ACAD SCIENCES, 2 EAST 63RD ST, NEW YORK, NY 10021
USARICKETTSIOSES: FROM GENOME TO PROTEOME, PATHOBIOLOGY, AND RICKETTSIAE AS AN INTERNATIONAL THREAT
Series: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Language: English Document Type: ARTICLE
Abstract: Ixodes scapularis ticks transmit Anaplasma phagocytophilum (Ap), agent of human granulocytic anaplasmosis (HGA). Invasion of neutrophil granulocytes (PMN) by Ap is the hallmark of the disease, but these short-lived phagocytes are not likely the sole cell type required for productive infection. We analyzed infection of microvascular endothelial cells during pathogenesis of anaplasmosis in vivo and in vitro. Organs from Ap-infected mice were processed for confocal microscopy 41 days p.i. Fluorescent labeling of heart and liver sections using anti-factor VIII and anti-MSP2 antibodies allowed colocalization of Ap and vascular endothelium, indicating infection. Ap rapidly invaded and grew within HMEC-1 human microvascular endothelial cells and readily transferred to PMN. Over 50% of PMN became infected within two hours of coincubation with HMEC-1. PMN adhered to, polarized, and migrated upon infected endothelial monolayers. The Ap receptor on human PMN is PSGL-1, and infected endothelial cells upregulate ICAM-1 (CD54), but the mechanisms of transfer of Ap remain unknown. To elucidate the cellular determinants involved, we tested relevant antibodies and lectins. Anti-PSGL-1 reduced infection of PMN, but did not inhibit adherence of PMN to Ap infected HMEC-1 cells while anti-CD18 did. Sialidase pretreatment increased, and EDTA and fucoidan decreased binding of Ap to HMEC-1, whereas several other lectins had no effect. An endothelial reservoir of Ap offers opportunities for ongoing, direct cell-to-cell infection of PMN, avoidance of host immune effectors, and completion of the Ap life cycle by infection of circulating leukocytes available for transfer to blood-feeding ticks.

2/7/9 (Item 1 from file: 135)
DIALOG(R)File 135:NewsRx Weekly Reports
(c) 2007 NewsRx. All rts. reserv.

0000192176 (THIS IS THE FULLTEXT)

P-selectin glycoprotein ligand-1 cross-linking induces activated T cell death

Blood Weekly, February 17, 2005, p.13

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT
AUDIENCE: Professional
WORD COUNT: 289

TEXT: P-selectin glycoprotein ligand-1 cross-linking induces activated T cell death.

According to published research from Taiwan, "Increasing evidence has shown that death signaling in T cells is regulated in a complicated way. Molecules other than death receptors can also trigger T-cell death.

"Here, we demonstrate for the first time that P-selectin glycoprotein ligand-1 (PSGL-1) or CD162 molecules crosslinked by an anti-PSGL-1 monoclonal antibody, TAB4, can trigger a death signal in activated T cells."

"In contrast to classic ***cell*** ***death***," S.C. Chen and colleagues said, "PSGL-1-mediated T-cell death is caspase independent. It involves translocation of apoptosis-inducing factor from mitochondria to nucleus and mitochondrial cytochrome c release."

"Ultrastructurally," the authors continued, "both peripheral condensation of chromatin and apoptotic body were observed in PSGL-1-mediated T- ***cell*** ***death***."

"Collectively, this study demonstrates a novel role for PSGL-1 in controlling activated T-cell death and, thus, advances our understanding of immune regulation," Chen concluded.

Chen and colleagues published their findings in Blood (Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells. Blood, 2004;104(10):3233-3242).

Additional information can be obtained by contacting R.H. Lin, Abgenomics, 2F 32, Lane 358, Juikuang Rd., Taipei 114, Taiwan.

The publisher of the journal Blood can be contacted at: American Society Hematology, 1900 M Street. NW Suite 200, Washington, DC 20036, USA.

The information in this article comes under the major subject areas of Proteomics, Apoptosis, T Lymphocytes, P-Selectin Glycoprotein Ligand-1 and Cross Linking.

This article was prepared by Blood Weekly editors from staff and other reports. Copyright 2005, Blood Weekly via NewsRx.com & NewsRx.net.

(c)Copyright 2005, Genomics & Genetics Weekly via NewsRx.com & NewsRx.net

2/7/10 (Item 2 from file: 135)
DIALOG(R)File 135:NewsRx Weekly Reports
(c) 2007 NewsRx. All rts. reserv.

0000133039 (THIS IS THE FULLTEXT)
E-selectin adhesion inhibits CD34 cells independently of PSGL-1
Biotech Business Week, April 12, 2004, p.475

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT
AUDIENCE: Professional
WORD COUNT: 404

TEXT: E-selectin adhesion inhibits CD34 cell activity in a PSGL-1-independent manner.

"Although both P- and E-selectin are constitutively expressed on bone marrow endothelial cells, their role in the regulation of hematopoiesis has only recently been investigated," hematologists in Australia noted.

In a previous study, I.G. Winkler and colleagues at the Peter

MacCallum Cancer Centre in Melbourne found that "P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is expressed by primitive human bone marrow CD34+ cells, mediates their adhesion to P-selectin, and, more importantly, inhibits their proliferation."

In their subsequent study, the collaborators demonstrated that "adhesion to E-selectin inhibits the proliferation of human CD34+ cells isolated either from human umbilical cord blood, adult mobilized blood, or steady-state bone marrow."

"Furthermore, a subpopulation, which does not contain the most primitive hematopoietic progenitor cells, undergoes apoptosis following E-selectin-mediated adhesion," test results revealed. "The same phenomenon was observed in cells isolated from mouse bone marrow."

"Using lineage-negative Sca-1+c-KIT+ bone marrow cells from PSGL-1-/- and wild-type mice, we establish that PSGL-1 is not the ligand involved in E-selectin-mediated growth inhibition and apoptosis," according to the report. "Moreover, stable transfection of the human myeloid cell line K562 (which does not express PSGL-1) with alpha(1,3) fucosyltransferase VII alone was sufficient to recapitulate the E-selectin-mediated growth inhibition and apoptosis observed in hematopoietic progenitor cells."

These findings indicate that "an E-selectin ligand(s) other than PSGL-1 transduces growth inhibitory and proapoptotic signals and requires posttranslational fucosylation to be functional," the researchers concluded.

Winkler and coauthors published their study in Blood (Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of ***PSGL*** -1. Blood, 2004;103(5):1685-1692).

For more information, contact I.G. Winkler, Peter MacCallum Cancer Centre, Adhesive Interactions and Cell Trafficking Laboratory, Stem Cell Biology Programme, Locked Bag 1, A'Beckett St., Melbourne, Vic 8006, Australia.

Publisher contact information for the journal Blood is: American Society of Hematology, 1900 M Street NW, Suite 200, Washington, DC 20036, USA.

The information in this article comes under the major subject areas of Hematology, Proteomics and Stem-Cell Research.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2004, Biotech Business Week via NewsRx.com & NewsRx.net.

(c) Copyright 2004, Angiogenesis Weekly via NewsRx.com & NewsRx.net

2/7/11 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

143476399 CA: 143(26)476399c PATENT

Anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

INVENTOR(AUTHOR): Lin, Rong-Hwa; Chang, Chung Nan; Chen, Pei-Jiun; Huang, Chiu-Chen

LOCATION: Taiwan,

ASSIGNEE: Abgenomics Corporation

PATENT: PCT International ; WO 2005110475 A2 DATE: 20051124

APPLICATION: WO 2005US16357 (20050510) *US 2004PV569892 (20040510)

PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A; C07K-016/28B; C12N-015/13B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR;

LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG;
PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ;
UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE
; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS;
IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA;
GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry
CA203XXX Biochemical Genetics
CA263XXX Pharmaceuticals

IDENTIFIERS: antibody human PSGL1 inflammation autoimmune disease allergy
transplant rejection, T cell cancer apoptosis immunomodulation Ig heavy
light chain

DESCRIPTORS:

Transplant rejection...

allotransplant; anti-human PSGL-1 antibodies for modulating T
cell-mediated immune response and treating inflammation, autoimmune
disease, allergy, transplant rejection and T cell cancer

Human... Antibodies and Immunoglobulins... T cell(lymphocyte)... Apoptosis

... Immunomodulators... Inflammation... Autoimmune disease... Allergy...

Transplant rejection... Genetic vectors... Eubacteria... Yeast... Plant
cell... Hybridoma... Nucleic acids... Mus musculus... Molecular cloning...

DNA sequences... Protein sequences...

anti-human PSGL-1 antibodies for modulating T cell-mediated immune
response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer

Biology...

cell, host; anti-human PSGL-1 antibodies for modulating T cell-mediated
immune response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

chimeric; anti-human PSGL-1 antibodies for modulating T cell-mediated
immune response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

fragments; anti-human PSGL-1 antibodies for modulating T cell-mediated
immune response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

heavy chain; anti-human PSGL-1 antibodies for modulating T
cell-mediated immune response and treating inflammation, autoimmune
disease, allergy, transplant rejection and T cell cancer

Insecta...

host cell; anti-human PSGL-1 antibodies for modulating T cell-mediated
immune response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

humanized; anti-human PSGL-1 antibodies for modulating T cell-mediated
immune response and treating inflammation, autoimmune disease, allergy,
transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

IgG1, const.; anti-human PSGL-1 antibodies for modulating T
cell-mediated immune response and treating inflammation, autoimmune
disease, allergy, transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

IgG2, const.; anti-human PSGL-1 antibodies for modulating T
cell-mediated immune response and treating inflammation, autoimmune
disease, allergy, transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

IgG3, const.; anti-human PSGL-1 antibodies for modulating T
cell-mediated immune response and treating inflammation, autoimmune

disease, allergy, transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

IgG4, const.; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

light chain; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

Animal cell...

mammalian; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

Antibodies and Immunoglobulins...

monoclonal; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

Glycoproteins...

PSGL-1 (P-selectin glycoprotein ligand-1); anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and

Immunity...

T cell-mediated; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

Transplant and Transplantation...

xenotransplant, rejection; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

CAS REGISTRY NUMBERS:

869760-83-8P 869760-84-9P 869760-82-7P 869760-87-2P 869760-85-0P
869760-89-4P 869760-86-1P 869760-88-3P amino acid sequence;
anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

869735-31-9DP 158329-15-8DP 869735-32-0DP 152510-28-6DP 869735-33-1DP
869735-34-2DP 869735-35-3DP 869735-36-4DP 785807-46-7DP
869735-37-5DP 869735-38-6DP 869735-39-7DP 869735-40-0DP
532987-93-2DP 869735-41-1DP 869735-42-2DP 869735-43-3DP derivs.,
anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

869760-62-3P 869760-92-9P 869760-91-8P 869760-94-1P 869760-90-7P
869760-93-0P nucleotide sequence; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

869761-35-3 869761-36-4 869761-37-5 869761-38-6 869761-39-7
869761-40-0 869761-41-1 869761-42-2 869761-43-3 869761-44-4
869761-45-5 869761-46-6 869761-47-7 869761-48-8 869761-49-9
869761-50-2 869761-51-3 869761-52-4 869761-53-5 869761-54-6
869761-55-7 869761-56-8 869761-57-9 869761-58-0 869761-59-1
869761-60-4 869761-61-5 869761-62-6 869761-63-7 869761-64-8
869761-65-9 869761-66-0 869761-67-1 869761-68-2 869761-69-3
869761-70-6 869761-71-7 869761-72-8 869761-73-9 869761-74-0
869761-75-1 869761-76-2 869761-77-3 869761-78-4 869761-79-5
869761-80-8 869761-81-9 869761-82-0 869761-83-1 869761-84-2
869761-85-3 869761-86-4 869761-87-5 869761-88-6 869761-89-7
869761-90-0 869761-91-1 869761-92-2 869761-93-3 869761-94-4
869761-95-5 869761-96-6 unclaimed sequence; anti-human PSGL-1 antibodies for modulating T cell-mediated immune response and treating inflammation, autoimmune disease, allergy, transplant rejection and T cell cancer

2/7/12 (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

143131837 CA: 143(8)131837x PATENT
Antibodies to P-selectin glycoprotein ligand-1
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel;
Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton,
Esther; Kanfi, Yariv; Ben-levy, Rachel; Szrajber, Tali
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20050152906 A1 DATE: 20050714
APPLICATION: US 2004881405 (20040630) *US 2003PV484235 (20030630)
PAGES: 70 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424155100; A61K-039/395A; A61K-031/7072B; A61K-031/60B;
A61K-031/522B; C07K-016/30B
SECTION:
CA215003 Immunochemistry
CA201XXX Pharmacology
CA208XXX Radiation Biochemistry
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: antibody sulfated tyrosine motif PSGL1
DESCRIPTORS:
Leukemia...
acute myeloid; immunotoxins of monoclonal antibodies to sulfated
tyrosine motif on PSGL-1 and glycoprotein GPIb
Cytolysis...
ADCC (antibody-dependent cellular cytotoxicity); by monoclonal
antibodies to sulfated tyrosine epitope on PSGL-1
Interferons...
 α , conjugates, with anti-PSGL-1 antibody; for therapy
Anthracyclines...
anti-PSGL-1 antibody conjugates; for therapy
Leukemia...
B-cell, acute; immunotoxins of monoclonal antibodies to sulfated
tyrosine motif on PSGL-1 and glycoprotein GPIb
Cell death...
by monoclonal antibodies to PSGL-1
Ricans...
conjugates, with anti-PSGL-1 antibody; for therapy
Protein motifs...
DXYD; on PSGL-1 and glycoprotein GPIb
Toxins...
exotoxins, conjugates, with anti-PSGL-1 antibody; for therapy
Drug delivery systems...
for immunotoxins targeting PSGL-1
Antibodies and Immunoglobulins...
fragments; to sulfated tyrosine motif on PSGL-1 and glycoprotein GPIb
Glycoproteins...
GPIb; monoclonal antibodies to sulfated tyrosine epitope on
Antibodies and Immunoglobulins...
IgG, monoclonal, Y1; to sulfated tyrosine motif on PSGL-1 and
glycoprotein GPIb
Tumor antigens...
immunodetection of
Antitumor agents... Neoplasm... Leukemia... Anticoagulants... Autoimmune
disease... Platelet aggregation inhibitors... Anti-inflammatory agents...
Antibacterial agents... Antiviral agents...
immunotoxins of monoclonal antibodies to sulfated tyrosine motif on
PSGL-1 and glycoprotein GPIb

Drug delivery systems...
immunotoxins; of monoclonal antibodies to sulfated tyrosine motif on
PSGL-1 and glycoprotein GPIb

Adhesion,biological...
inhibitors; immunotoxins of monoclonal antibodies to sulfated tyrosine
motif on PSGL-1 and glycoprotein GPIb

Endocytosis...
is induced by monoclonal antibodies to PSGL-1

Polymers,biological studies...
lipophilic; for delivery of immunotoxins targeting PSGL-1

Drug delivery systems...
liposomes; for delivery of immunotoxins targeting PSGL-1

Diagnosis... Prognosis... Anti-AIDS agents...
monoclonal antibodies to PSGL-1

Immunotherapy...
monoclonal antibodies to PSGL-1 for

Human...
monoclonal antibodies to PSGL-1 for immunotherapy

AIDS(disease)...
monoclonal antibodies to PSGL-1 for immunotherapy of

Human immunodeficiency virus...
monoclonal antibodies to PSGL-1 for prevention of infection by

T cell(lymphocyte)...
monoclonal antibodies to sulfated tyrosine epitope on PSGL-1

Lymphocyte...
natural killer cell; monoclonal antibodies to sulfated tyrosine epitope
on PSGL-1

Epitopes...
on PSGL-1 and GPIb for monoclonal antibodies

Glycoproteins...
PSGL-1 (P-selectin glycoprotein ligand-1); monoclonal antibodies to
sulfated tyrosine epitope on

Carcinoma...
pulmonary small-cell; immunotoxins of monoclonal antibodies to sulfated
tyrosine motif on PSGL-1 and glycoprotein GPIb

Artery,disease...
restenosis, inhibitors; immunotoxins of monoclonal antibodies to
sulfated tyrosine motif on PSGL-1 and glycoprotein GPIb

Leukocyte...
rolling; monoclonal antibodies to PSGL-1 for inhibition of

Lung,neoplasm...
small-cell carcinoma; immunotoxins of monoclonal antibodies to sulfated
tyrosine motif on PSGL-1 and glycoprotein GPIb

Imaging...
tumor; radiolabeled monoclonal antibodies to PSGL-1

Immunoradiotherapy...
with monoclonal antibodies to PSGL-1

CAS REGISTRY NUMBERS:

15750-15-9D 14885-78-0D 15765-79-4D 14913-89-4D 14378-53-1D
14133-76-7D 14304-79-1D 14390-71-7D 14390-73-9D 14041-48-6D
14391-22-1D 14900-13-1D 15715-08-9D 14158-32-8D 10043-66-0D
14834-67-4D 15678-91-8D 14932-42-4D 10098-91-6D 15776-20-2D
15765-39-6D 13981-56-1D 15756-62-4D 15758-35-7D 13968-53-1D
14331-95-4D 33455-08-2D 13982-78-0D 14119-09-6D 15757-14-9D
anti-PSGL-1 antibody conjugates, biological studies, for therapy

59277-89-3D 82410-32-0D 30516-87-1D 73963-72-1D 9041-08-1D 50-78-2D
74711-43-6D 52549-17-4D 90101-16-9D 15307-86-5D 15687-27-1D
51146-56-6D 38194-50-2D 22204-53-1D 87344-06-7D 169590-42-5D
53-86-1D 162011-90-7D 51803-78-2D 75706-12-6D 173146-27-5D
262423-20-1D 425603-01-6D 83712-60-1D 50-18-0D 75037-46-6D
23214-92-8D 20830-81-3D 58957-92-9D 66211-92-5D 39472-31-6D
56420-45-2D 63521-85-7D 80790-68-7D 79867-78-0D 108852-90-0D

15663-27-1D 33069-62-4D 113440-58-7D 57-22-7D 147-94-4D 53-03-2D
21679-14-1D 305-03-3D 127-07-1D 85622-93-1D 50-35-1D 11056-06-7D
anti-PSGL-1 antibody conjugates, for therapy
9004-54-0 biological studies, for delivery of immunotoxins targeting
PSGL-1
21442-01-3 for delivery of immunotoxins targeting PSGL-1
485815-21-2 858699-94-2 827572-83-8 827572-91-8 858611-43-5
858611-45-7 858611-47-9 858611-49-1 858611-51-5 858611-53-7
858611-55-9 858611-57-1 442528-29-2 442528-30-5 640724-04-5
640723-68-8 640723-95-1 122024-47-9 64134-30-1 848861-13-2
858611-67-3 640723-69-9 unclaimed sequence; antibodies to P-selectin
glycoprotein ligand-1

2/7/13 (Item 3 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142353888 CA: 142(19)353888h PATENT
Antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb
and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and
inflammation
INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther;
Hagay, Yocheved; Ben-levy, Rachel; Nisgav, Yael; Kanfi, Yariv
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20050069955 A1 DATE: 20050331
APPLICATION: US 2004880922 (20040630) *US 2003PV484061 (20030630)
PAGES: 74 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007100; G01N-033/53A; C07K-016/18B
SECTION:
CA215003 Immunochemistry
CA201XXX Pharmacology
CA203XXX Biochemical Genetics
CA209XXX Biochemical Methods
CA263XXX Pharmaceuticals
IDENTIFIERS: antibody fragment PSGL1 GPIb CCR5 cancer inflammation
autoimmune disease, infection leukemia metastasis heavy light chain
sulfated epitope PSGL1
DESCRIPTORS:
Leukemia...
acute lymphocytic; antibodies and fragments specific to sulfated
epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of
cancer, autoimmune disease and inflammation
Leukemia...
acute myeloid; antibodies and fragments specific to sulfated epitope of
PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer,
autoimmune disease and inflammation
Platelet(blood)...
aggregation, inhibition; antibodies and fragments specific to sulfated
epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of
cancer, autoimmune disease and inflammation
Antibodies and Immunoglobulins... Epitopes... Vitronectin... Amyloid
precursor proteins... Fibronectins... Multiple myeloma... Platelet(blood)
... Polymorphonuclear leukocyte... Lymphocyte... Monocyte... Drug delivery
systems... Immunotherapy... Prognosis... Antitumor agents... Imaging agents
... Genetic vectors... Culture media... Affinity... Disease, animal...
Infection... AIDS(disease)... Human immunodeficiency virus 1...
Inflammation... Autoimmune disease... Leukemia... Susceptibility(genetic)
... Apoptosis... T cell(lymphocyte)... Phage display library... Filamentous
bacteriophage... Inorganic compounds... Molecular cloning... DNA sequences
... Protein sequences... Drug screening... Anti-inflammatory agents...

Human immunodeficiency virus... Anti-infective agents... Antiviral agents
... Cardiovascular system,disease... Human... Peptidomimetics...
antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb
and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and
inflammation

Chromogranins...
B; antibodies and fragments specific to sulfated epitope of PSGL-1,
GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune
disease and inflammation

Leukemia...
B-cell, acute; antibodies and fragments specific to sulfated epitope of
PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer,
autoimmune disease and inflammation

Samples...
biol.; antibodies and fragments specific to sulfated epitope of PSGL-1,
GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune
disease and inflammation

Chemokine receptors...
C-C (cysteine-cysteine chemokine receptors); antibodies and fragments
specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis
and therapy of cancer, autoimmune disease and inflammation

Diagnosis...
cancer; antibodies and fragments specific to sulfated epitope of
PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer,
autoimmune disease and inflammation

Drug delivery systems...
carriers; antibodies and fragments specific to sulfated epitope of
PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer,
autoimmune disease and inflammation

Chemokine receptors...
CCR2; antibodies and fragments specific to sulfated epitope of PSGL-1,
GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune
disease and inflammation

Chemokine receptors...
CCR2b; antibodies and fragments specific to sulfated epitope of PSGL-1,
GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune
disease and inflammation

Chemokine receptors...
CCR3; antibodies and fragments specific to sulfated epitope of PSGL-1,
GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune
disease and inflammation

Chemokine receptors...
CCR5; antibodies and fragments specific to sulfated epitope of PSGL-1,
GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune
disease and inflammation

Biology...
cell, recombinant host; antibodies and fragments specific to sulfated
epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of
cancer, autoimmune disease and inflammation

Immunity...
cell-mediated, antibody-dependent; antibodies and fragments specific to
sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy
of cancer, autoimmune disease and inflammation

Leukemia...
chronic lymphocytic; antibodies and fragments specific to sulfated
epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of
cancer, autoimmune disease and inflammation

Antibodies and Immunoglobulins...
conjugates; antibodies and fragments specific to sulfated epitope of
PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer,
autoimmune disease and inflammation

Chemokine receptors...

CXCR3; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Chemokine receptors...

CXCR4; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Chemokine receptors...

CXCR8; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Proteoglycans, biological studies...

dermatan sulfate; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Proteoglycans, biological studies...

dermatan sulfate-contg.; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Immunity...

disorder; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Lymphocyte...

effector cell; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Lipids, biological studies... Carbohydrates, biological studies...

Peptides, biological studies... Glycolipids... Glycoproteins... Lipoproteins... Lipopolysaccharides...

epitope; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Antibodies and Immunoglobulins...

fragments; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Fibrinogens...

γ chain; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Glycoproteins...

GPIb; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Antibodies and Immunoglobulins...

heavy chain; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Secretogranins...

II; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Drug delivery systems...

immunoconjugates; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Diagnosis...

immunodiagnosis; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Drug delivery systems...

immunotoxins; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Heart,disease...
 infarction; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Antibodies and Immunoglobulins...
 light chain; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Neoplasm...
 metastasis; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Antibodies and Immunoglobulins...
 monoclonal; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Lymphocyte...
 natural killer cell; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Molecular association...
 protein-protein interaction, sulfated tyrosine-dependent; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Glycoproteins...
 PSGL-1 (P-selectin glycoprotein ligand-1); antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Cell migration...
 rolling; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Receptors...
 seven-transmembrane; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Molecules...
 small inorg.; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Leukemia...
 T-cell, acute; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

Infection...
 viral; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

CAS REGISTRY NUMBERS:

848885-80-3P 848886-08-8P 848886-09-9P 848886-10-2P 848886-11-3P
 848886-12-4P amino acid sequence; antibodies and fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis and therapy of cancer, autoimmune disease and inflammation

640723-69-9 485815-21-2 848886-07-7 212783-31-8 442528-29-2
 837362-14-8 837362-15-9 837362-16-0 837362-17-1 837362-18-2
 837362-19-3 837362-20-6 837362-21-7 642928-14-1 212783-20-5
 837362-22-8 837362-23-9 848861-12-1 837362-24-0 837362-25-1
 837362-26-2 837362-27-3 837362-28-4 837362-30-8 837362-31-9
 837362-32-0 837362-33-1 837362-35-3 837362-37-5 640723-99-5

330163-86-5 138757-15-0 9073-92-1 9001-24-5 113189-02-9 9001-28-9
81604-65-1 9011-97-6 9002-61-3 80295-48-3 9002-76-0 antibodies and
fragments specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for
diagnosis and therapy of cancer, autoimmune disease and inflammation
848886-47-5 848886-48-6 848886-49-7 848886-50-0 848886-51-1
848886-52-2 unclaimed nucleotide sequence; antibodies and fragments
specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis
and therapy of cancer, autoimmune disease and inflammation
122024-47-9 2543-43-3 837362-29-5 837362-38-6 837362-39-7 837362-40-0
64134-30-1 848861-13-2 unclaimed sequence; antibodies and fragments
specific to sulfated epitope of PSGL-1, GPIb and/or CCR5 for diagnosis
and therapy of cancer, autoimmune disease and inflammation

2/7/14 (Item 4 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142349113 CA: 142(19)349113j (CORRECTION OF 142(9)148820p) PATENT
Anti-PSGL-1 antibodies, and diagnostic and therapeutic use
INVENTOR(AUTHOR): Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel;
Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton,
Esther; Kanfi, Yariv; Ben-Levy, Rachel
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200505455 A2 DATE: 20050120
APPLICATION: WO 2004US21099 (20040630) *US 2003610840 (20030630)
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG
SECTION:
CA201012 Pharmacology
CA209XXX Biochemical Methods
CA215XXX Immunochemistry
CA226XXX Biomolecules and Their Synthetic Analogs
IDENTIFIERS: PSGL1 antibody conjugate diagnostic therapeutic,
morpholinodaunorubicin antibody conjugate prepn diagnostic therapeutic
DESCRIPTORS:
Leukemia...
acute myeloid; anti-PSGL-1 antibodies, and diagnostic and therapeutic
use
Platelet(blood)...
aggregation; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Interferons...
 α , antibody conjugates; anti-PSGL-1 antibodies, and diagnostic
and therapeutic use
Antibodies and Immunoglobulins... Neoplasm... Leukemia...
Adhesion,biological... Thrombosis... Autoimmune disease... Immunomodulators
... Inflammation... Epitopes... Drug delivery systems... Diagnosis... Test
kits... Cytotoxic agents... Immunostimulants... T cell(lymphocyte)... Cell
death... Human immunodeficiency virus... AIDS(disease)... Anti-AIDS agents
... Human... Platelet aggregation inhibitors... Tumor antigens... Monocyte

- ... Mononuclear cell(leukocyte)... Apoptosis...
 - anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Aggregation...
 - antiaggregation agents, antibody conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Antitumor agents... Drugs... Anticoagulants... Cardiovascular agents...
- Antibacterial agents... Antiviral agents... Anti-inflammatory agents...
- Toxins... Radionuclides,biological studies... Imaging agents... Ricins...
- Anthracyclines...
 - antibody conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Cytotoxicity...
 - antibody-dependent; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Infection...
 - bacterial; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Radionuclides,biological studies...
 - β emitters, antibody conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Animal cell...
 - cell rolling; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Leukemia...
 - chronic B-lymphocytic; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Leukemia...
 - chronic myelocytic; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Antibodies and Immunoglobulins...
 - conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- T cell(lymphocyte)...
 - cytotoxic; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Gamma ray... X-ray...
 - emitters, antibody conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Pseudomonas...
 - exotoxin, antibody conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Toxins...
 - exotoxins, Pseudomonas, antibody conjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Antibodies and Immunoglobulins...
 - fragments; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- T cell(lymphocyte)...
 - $\gamma\delta$; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Glycoproteins...
 - GPIb; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Neoplasm...
 - hematol.; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Antibodies and Immunoglobulins...
 - IgG; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Chromatography...
 - immunoaffinity; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Drug delivery systems...
 - immunoconjugates; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Antibodies and Immunoglobulins...
 - KPL-1, PL1, and PL2; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
- Polymers,biological studies...

lipophilic; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Drug delivery systems...
liposomes; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Neoplasm...
metastasis; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Lymphocyte...
natural killer cell; anti-PSGL-1 antibodies, and diagnostic and
therapeutic use
Cell activation...
NK cell; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Selectins...
P-; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Cell aggregation...
platelet; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Platelet(blood)... Leukocyte...
platelet-leukocyte interaction; anti-PSGL-1 antibodies, and diagnostic
and therapeutic use
Glycoproteins...
PSGL-1 (P-selectin glycoprotein ligand-1); anti-PSGL-1 antibodies, and
diagnostic and therapeutic use
Carcinoma...
pulmonary small-cell; anti-PSGL-1 antibodies, and diagnostic and
therapeutic use
Artery,disease...
restenosis; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Leukocyte... Neutrophil...
rolling; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Lung,neoplasm...
small-cell carcinoma; anti-PSGL-1 antibodies, and diagnostic and
therapeutic use
Neoplasm...
solid; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Neoplasm...
tumor cell purging; anti-PSGL-1 antibodies, and diagnostic and
therapeutic use
Infection...
viral; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Antibodies and Immunoglobulins...
Y1; anti-PSGL-1 antibodies, and diagnostic and therapeutic use
Endocytosis...
Y1-IgG-mediated; anti-PSGL-1 antibodies, and diagnostic and therapeutic
use

CAS REGISTRY NUMBERS:

59277-89-3 82410-32-0 30516-87-1 73963-72-1 9041-08-1 50-78-2
74711-43-6 52549-17-4 90101-16-9 15307-86-5 15687-27-1 51146-56-6
38194-50-2 22204-53-1 169590-42-5 53-86-1 162011-90-7 51803-78-2
75706-12-6 173146-27-5 262423-20-1 425603-01-6 83712-60-1 50-18-0
74397-12-9 640734-07-2 9004-61-9 75037-46-6 12585-85-2 12587-46-1
23214-92-8 20830-81-3 58957-92-9 66211-92-5 39472-31-6 56420-45-2
63521-85-7 80790-68-7 79867-78-0 108852-90-0 15663-27-1 33069-62-4
113440-58-7 57-22-7 147-94-4 640723-69-9 53-03-2 21679-14-1
305-03-3 127-07-1 85622-93-1 50-35-1 11056-06-7 21442-01-3
87085-11-8 174722-31-7 126775-97-1 23541-50-6 827572-79-2
827572-80-5 81186-33-6 827572-81-6 114035-84-6 827572-82-7
6066-82-6 827572-83-8 827572-84-9 827572-85-0 827572-86-1
827572-87-2 827572-88-3 827572-90-7 827572-91-8 827572-92-9
827572-93-0 827572-94-1 827572-95-2 827572-96-3 827572-97-4
827572-98-5 827572-99-6 827573-00-2 827573-01-3 827573-02-4
827573-03-5 827573-04-6 anti-PSGL-1 antibodies, and diagnostic and
therapeutic use
87344-06-7D antibody conjugates, Amtolmetin guacil; anti-PSGL-1
antibodies, and diagnostic and therapeutic use

15750-15-9 14885-78-0 15765-79-4 14913-89-4 14378-53-1 14133-76-7
 14304-79-1 14390-71-7 14390-73-9 14041-48-6 14391-22-1 14900-13-1
 15715-08-9 14158-32-8 10043-66-0 14834-67-4 15678-91-8 10098-91-6
 15776-20-2 15765-39-6 13981-56-1 15756-62-4 15758-35-7 13968-53-1
 14331-95-4 13982-78-0 14119-09-6 15757-14-9 9004-54-0 124-04-9
 biological studies, anti-PSGL-1 antibodies, and diagnostic and
 therapeutic use
 848792-64-3 848725-73-5 848725-74-6 848725-75-7 848725-76-8
 848725-77-9 848725-78-0 848725-79-1 848725-80-4 848725-81-5
 848725-82-6 848725-83-7 848725-84-8 848725-85-9 442528-29-2
 848955-14-6 442528-30-5 640724-04-5 640723-68-8 848725-86-0
 unclaimed protein sequence; anti-PSGL-1 antibodies, and diagnostic and
 therapeutic use

2/7/15 (Item 5 from file: 399)
 DIALOG(R) File 399:CA SEARCH(R)
 (c) 2007 American Chemical Society. All rts. reserv.

141047313 CA: 141(4)47313z PATENT
 Multimeric polypeptide modulators of P-selectin glycoprotein ligand 1,
 and their therapeutic use
 INVENTOR(AUTHOR): Lin, Rong-Hwa; Chang, Chung Nan
 LOCATION: Taiwan,
 PATENT: U.S. Pat. Appl. Publ. ; US 20040116333 A1 DATE: 20040617
 APPLICATION: US 662906 (20030915) *US PV310196 (20010803) *US 51497
 (20020118)
 PAGES: 29 pp., Cont.-in-part of U.S. Ser. No. 51,497. CODEN: USXXCO
 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: 514008000; A61K-038/17A; A61K-038/16B
 SECTION:
 CA201007 Pharmacology
 IDENTIFIERS: polypeptide multimer PSGL1 modulator therapeutic T cell
 depletion apoptosis, NK cell depletion apoptosis polypeptide multimer
 PSGL1 modulator therapeutic, inflammation allergy treatment polypeptide
 multimer PSGL1 modulator, autoimmune disease transplant rejection
 treatment polypeptide multimer PSGL1 modulator
 DESCRIPTORS:
 T cell(lymphocyte)....
 activation; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Transplant and Transplantation...
 allotransplant, skin; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Transplant and Transplantation... Transplant rejection... Skin...
 allotransplant; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Antigens... Antibodies and Immunoglobulins...
 anti-PSGL-1 antibody antigen-binding domain; multimeric polypeptide
 modulators of PSGL-1, and therapeutic use
 Protein motifs...
 binding domain; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Receptors...
 cell surface receptor binding region; multimeric polypeptide modulators
 of PSGL-1, and therapeutic use
 Selectins...
 E-, extracellular domain; multimeric polypeptide modulators of PSGL-1,
 and therapeutic use
 Antibodies and Immunoglobulins...
 heavy chain, const. region; multimeric polypeptide modulators of

PSGL-1, and therapeutic use
 Diabetes mellitus...
 insulin-dependent; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Selectins...
 L-, extracellular domain; multimeric polypeptide modulators of PSGL-1,
 and therapeutic use
 Antibodies and Immunoglobulins...
 monoclonal; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 T cell(lymphocyte)... Immunosuppressants... Human... Proteins... Signal
 transduction,biological... Cytotoxic agents... Phage display library...
 Disulfide group... Inflammation... Anti-inflammatory agents... Transplant
 and Transplantation... Transplant rejection... Allergy... Allergy
 inhibitors... Antitumor agents... Drug delivery systems... B
 cell(lymphocyte)... CD19(antigen)... CD3(antigen)... CD4-positive T cell...
 CD8-positive T cell... CD4(antigen)... CD8(antigen)... Interleukin 2...
 Antidiabetic agents... Mononuclear cell(leukocyte)... Autoimmune disease...
 multimeric polypeptide modulators of PSGL-1, and therapeutic use
 Lymphocyte...
 natural killer cell; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Selectins...
 P-, extracellular domain; multimeric polypeptide modulators of PSGL-1,
 and therapeutic use
 Fusion proteins(chimeric proteins)...
 P-selectin-Fc; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Glycoproteins...
 PSGL-1 (P-selectin glycoprotein ligand-1); multimeric polypeptide
 modulators of PSGL-1, and therapeutic use
 Crosslinking...
 PSGL-1; multimeric polypeptide modulators of PSGL-1, and therapeutic
 use
 Spleen...
 splenocyte; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Cell activation...
 T cell; multimeric polypeptide modulators of PSGL-1, and therapeutic
 use
 Neoplasm...
 T-cell cancer; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 Antigens...
 TAIP; multimeric polypeptide modulators of PSGL-1, and therapeutic use
 Thymus gland...
 thymocyte; multimeric polypeptide modulators of PSGL-1, and therapeutic
 use
 Tumor necrosis factors...
 TNF- α ; multimeric polypeptide modulators of PSGL-1, and
 therapeutic use
 CAS REGISTRY NUMBERS:
 705266-51-9 64134-30-1 unclaimed sequence; multimeric polypeptide
 modulators of P-selectin glycoprotein ligand 1, and their therapeutic
 use

2/7/16 (Item 6 from file: 399)
 DIALOG(R) File 399:CA SEARCH(R)
 (c) 2007 American Chemical Society. All rts. reserv.

140092589 CA: 140(7)92589j PATENT

Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit

LOCATION: USA

ASSIGNEE: Savient Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200403166 A2 DATE: 20040108

APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)

PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA201XXX Pharmacology

CA203XXX Biochemical Genetics

CA209XXX Biochemical Methods

CA263XXX Pharmaceuticals

IDENTIFIERS: PSGL1 epitope antibody scFv cancer infection inflammation autoimmune disease

DESCRIPTORS:

T cell(lymphocyte)...

activation; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Leukemia...

acute lymphocytic; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Leukemia...

acute myelogenous; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Interferons...

α; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Anthracyclines... Antibodies and Immunoglobulins... Antitumor agents...

Prognosis... Leukemia... Autoimmune disease... Inflammation... Infection...

Anti-inflammatory agents... Anti-infective agents... Leukocyte...

Platelet(blood)... Epitopes... Fibrinogens... Selectins... Multiple myeloma

... Lipids,biological studies... Carbohydrates,biological studies...

Peptides,biological studies... Glycolipids... Glycoproteins... Lipoproteins

... Lipopolysaccharides... Drugs... Thrombosis... Anticoagulants...

Antibacterial agents... Antiviral agents... Toxins...

Radionuclides,biological studies... Imaging agents... Ricins... Genetic vectors... Culture media... Human immunodeficiency virus... Phage display

library... Molecules... Protein sequences... Anti-AIDS agents... Human...

antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Cytotoxicity...

antibody-dependent; antibodies or scFv fragments specific to PSGL-1

epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Leukemia...

B-cell, acute; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Leukemia...

B-cell; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Diagnosis...

cancer; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Drug delivery systems...

carriers; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Biology...

cell, host; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Cell migration...

cell rolling; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Gamma ray... X-ray...

emitters; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Pseudomonas...

exotoxin; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Toxins...

exotoxins, PE40 and PE38; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and

Antibodies and Immunoglobulins...

fragments, scFv; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Glycoproteins...

GP1b; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Drug delivery systems...

immunoconjugates; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Drug delivery systems...

immunotoxins; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Cell aggregation... Adhesion, biological...

inhibitors; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Polymers, biological studies...

lipophilic; antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia

Drug delivery systems...

liposomes; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

Neoplasm...

metastasis; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

Antibodies and Immunoglobulins...

monoclonal; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

Cell death... Apoptosis...

mortality; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

Lymphocyte...

natural killer cell, stimulation; antibodies or scFv fragments specific
to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of
cancer, inflammation, infection, autoimmune disease, metasta

Amino acids, biological studies...

neg. charged; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

Glycoproteins...

PSGL-1 (P-selectin glycoprotein ligand-1); antibodies or scFv fragments
specific to PSGL-1 epitopes useful for diagnosis, prognosis and
treatment of cancer, inflammation, infection, autoimmune disease

Artery, disease...

restenosis, inhibitors; antibodies or scFv fragments specific to PSGL-1
epitopes useful for diagnosis, prognosis and treatment of cancer,
inflammation, infection, autoimmune disease, metastasis and le

T cell (lymphocyte)...

stimulation; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

Functional groups...

sulfated moiety; antibodies or scFv fragments specific to PSGL-1
epitopes useful for diagnosis, prognosis and treatment of cancer,
inflammation, infection, autoimmune disease, metastasis and leukemia

Leukemia...

T-cell, acute; antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia

CAS REGISTRY NUMBERS:

643147-81-3P 212783-31-8 642928-14-1 212783-20-5 639019-64-0
442528-29-2 639019-66-2 639019-68-4 639019-70-8 639019-72-0
639019-74-2 639019-76-4 641636-20-6 640723-99-5 639019-58-2
641636-21-7 641636-22-8 330163-86-5 641636-23-9 59277-89-3
82410-32-0 30516-87-1 73963-72-1 9041-08-1 50-78-2 74711-43-6
52549-17-4 90101-16-9 15307-86-5 15687-27-1 51146-56-6 38194-50-2
22204-53-1 169590-42-5 53-86-1 162011-90-7 51803-78-2 75706-12-6
173146-27-5 262423-20-1 425603-01-6 50-18-0 74397-12-9 68206-94-0
9004-61-9 75037-46-6 23214-92-8 20830-81-3 58957-92-9 66211-92-5
39472-31-6 56420-45-2 63521-85-7 80790-68-7 79867-78-0 108852-90-0
15663-27-1 33069-62-4 113440-58-7 57-22-7 147-94-4 53-03-2
21679-14-1 305-03-3 127-07-1 85622-93-1 50-35-1 11056-06-7
21442-01-3 antibodies or scFv fragments specific to PSGL-1 epitopes
useful for diagnosis, prognosis and treatment of cancer, inflammation,
infection, autoimmune disease, metastasis and leukemia
15750-15-9 14885-78-0 35014-81-4 51692-56-9 51692-52-5 378784-45-3
14390-71-7 378784-46-4 378784-50-0 14041-48-6 14391-22-1

14900-13-1 15715-08-9 14158-32-8 10043-66-0 14834-67-4 378253-17-9
 14932-42-4 10098-91-6 15776-20-2 15765-39-6 13981-56-1 15756-62-4
 15758-35-7 13968-53-1 14331-95-4 33455-08-2 14119-09-6 15757-14-9
 9004-54-0 13982-78-0 biological studies, antibodies or scFv fragments
 specific to PSGL-1 epitopes useful for diagnosis, prognosis and
 treatment of cancer, inflammation, infection, autoimmune disease,
 metastasis and leukemia
 12587-47-2 12587-46-1 12585-85-2 emitters; antibodies or scFv fragments
 specific to PSGL-1 epitopes useful for diagnosis, prognosis and
 treatment of cancer, inflammation, infection, autoimmune disease,
 metastasis and leukemia
 956-46-7 polypeptides contg.; antibodies or scFv fragments specific to
 PSGL-1 epitopes useful for diagnosis, prognosis and treatment of
 cancer, inflammation, infection, autoimmune disease, metastasis and
 leukemia
 642928-15-2D sulfated derivs., antibodies or scFv fragments specific to
 PSGL-1 epitopes useful for diagnosis, prognosis and treatment of
 cancer, inflammation, infection, autoimmune disease, metastasis and
 leukemia
 212783-21-6 442527-66-4 442527-67-5 145646-22-6 640723-69-9
 642928-16-3 442527-56-2 642928-17-4 642928-18-5 642928-19-6
 643355-85-5 643355-86-6 unclaimed sequence; antibodies or scFv
 fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis
 and treatment of cancer, inflammation, infection, autoimmune disease,
 metastasis and leukemia

2/7/17 (Item 7 from file: 399)
 DIALOG(R) File 399:CA SEARCH(R)
 (c) 2007 American Chemical Society. All rts. reserv.

137062090 CA: 137(5)62090k JOURNAL
 Selectin-mediated interactions regulate cytokine networks and macrophage
 heme oxygenase-1 induction in cardiac allograft recipients
 AUTHOR(S): Coito, Ana J.; Shaw, Gray D.; Li, Jiye; Ke, Bibo; Ma, Jeffrey;
 Busuttill, Ronald W.; Kupiec-Weglinski, Jerzy W.
 LOCATION: Dumont-UCLA Transplant Center, Department of Surgery, UCLA
 School of Medicine, Los Angeles, CA, USA
 JOURNAL: Lab. Invest. (Laboratory Investigation) DATE: 2002 VOLUME: 82
 NUMBER: 1 PAGES: 61-70 CODEN: LAINAW ISSN: 0023-6837 LANGUAGE:
 English PUBLISHER: Lippincott Williams & Wilkins
 SECTION:
 CA215010 Immunochemistry
 IDENTIFIERS: selectin cytokine network macrophage heme oxygenase 1 heart
 allograft
 DESCRIPTORS:
 Transplant and Transplantation...
 allotransplant, heart; P-selectin/PSGL-1-mediated interactions in
 regulation of cytokine networks and macrophage heme oxygenase-1
 induction in cardiac allograft recipients
 Heart...
 allotransplant; P-selectin/PSGL-1-mediated interactions in regulation
 of cytokine networks and macrophage heme oxygenase-1 induction in
 cardiac allograft recipients
 Transplant rejection...
 allotransplant; P-selectin/PSGL-1-mediated interactions in regulation
 of cytokine networks and macrophage heme oxygenase-1 induction in
 cardiac allograft recipients in relation to
 Interferons...
 gamma; P-selectin/PSGL-1-mediated interactions in regulation of
 cytokine networks and macrophage heme oxygenase-1 induction in cardiac
 allograft recipients

T cell(lymphocyte)...

helper cell/inducer, TH1; P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients in relation to Th1 cell d

Heart,disease...

infarction; P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients in relation to

Immunoglobulins...

M; P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients

Selectins...

P-; P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients

Interleukin 1 β ... Interleukin 2... Macrophage... Monocyte

chemoattractant protein-1...

P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients

Apoptosis...

P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients in relation to myocardial infarction and

Cell differentiation...

P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients in relation to Th1 cell differentiation

Glycoproteins...

PSGL-1 (P-selectin glycoprotein ligand-1); P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients

CAS REGISTRY NUMBERS:

9059-22-7 1; P-selectin/PSGL-1-mediated interactions in regulation of cytokine networks and macrophage heme oxygenase-1 induction in cardiac allograft recipients

?